{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:34:48Z","timestamp":1792010088908,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2015,10,9]],"date-time":"2015-10-09T00:00:00Z","timestamp":1444348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s40265-015-0479-6","type":"journal-article","created":{"date-parts":[[2015,10,9]],"date-time":"2015-10-09T06:48:46Z","timestamp":1444373326000},"page":"1935-1940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Sebelipase Alfa: First Global Approval"],"prefix":"10.1007","volume":"75","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,9]]},"reference":[{"issue":"1","key":"479_CR1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2014.04.003","volume":"235","author":"Z Reiner","year":"2014","unstructured":"Reiner Z, Guardamagna O, Nair D, et al. Lysosomal acid lipase deficiency\u2014an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis. 2014;235(1):21\u201330.","journal-title":"Atherosclerosis"},{"issue":"6","key":"479_CR2","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jhep.2013.02.014","volume":"58","author":"DL Bernstein","year":"2013","unstructured":"Bernstein DL, H\u00fclkova H, Bialer MG, et al. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013;58(6):1230\u201343.","journal-title":"J Hepatol"},{"issue":"3","key":"479_CR3","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/hep.26366","volume":"58","author":"G Grabowski","year":"2013","unstructured":"Grabowski G. Therapy for lysosomal acid lipase deficiency: replacing a missing link. Hepatology. 2013;58(3):850\u20132.","journal-title":"Hepatology"},{"issue":"2","key":"479_CR4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/15748898113089990002","volume":"8","author":"L Urbanelli","year":"2013","unstructured":"Urbanelli L, Sagini K, Polidoro M, et al. Therapeutic approaches for lysosomal storage diseases: a patent update. Recent Pat CNS Drug Discov. 2013;8(2):91\u2013109.","journal-title":"Recent Pat CNS Drug Discov"},{"key":"479_CR5","unstructured":"European Medicines Agency. Kanuma (sebelipase alfa): summary of product characteristics. 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004004\/WC500192715.pdf . Accessed 02 Sep 2015."},{"key":"479_CR6","unstructured":"Alexion Pharmaceuticals. LAL deficiency and sebelipase alfa. 2015. http:\/\/alexion.com\/Research-Development\/OurResearch\/LAL-Deficiency-and-Sebelipase-Alfa . Accessed 19 Aug 2015."},{"key":"479_CR7","unstructured":"European Medicines Agency. Kanuma (sebelipase alfa)\u2014summary of opinion. 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/004004\/WC500188768.pdf . Accessed 19 Aug 2015."},{"key":"479_CR8","unstructured":"Alexion Pharmaceuticals. Alexion completes acquisition of Synageva [media release]. 2015. http:\/\/news.alexionpharma.com\/press-release\/company-news\/alexion-completes-acquisition-synageva . Accessed 19 Aug 2015."},{"issue":"3","key":"479_CR9","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/hep.26289","volume":"58","author":"M Balwani","year":"2013","unstructured":"Balwani M, Breen C, Enns GM, et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology. 2013;58(3):950\u20137.","journal-title":"Hepatology"},{"key":"479_CR10","doi-asserted-by":"crossref","unstructured":"Quinn AG, Harvey A, Chen M, et al. SBC-102, a recombinant enzyme replacement therapy, corrects key abnormalities due to lysosomal acid lipase deficiency [abstract]. In: American Society of Human Genetics Annual Meeting 2010.","DOI":"10.1016\/j.ymgme.2010.11.125"},{"issue":"Suppl 1","key":"479_CR11","first-page":"E20","volume":"52","author":"M Leavitt","year":"2011","unstructured":"Leavitt M, Hu W, Canty D, et al. Efficacy of SBC-102, a recombinant enzyme replacement therapy, across a broad range of doses in an in vivo model of lysosomal acid lipase deficiency [abstract no. PA-H-0036]. J Pediatr Gastroenterol Nutr. 2011;52(Suppl 1):E20.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"479_CR12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2013.04.016","volume":"59","author":"PE Thelwall","year":"2013","unstructured":"Thelwall PE, Smith FE, Leavitt MC, et al. Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: non-invasive identification and treatment monitoring by magnetic resonance. J Hepatol. 2013;59(3):543\u20139.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"479_CR13","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.1016\/S0168-8278(11)60902-1","volume":"54","author":"M Leavitt","year":"2011","unstructured":"Leavitt M, Burt AD, Hu W, et al. Recombinant lysosomal acid lipase normalizes liver weight, transaminases and histopathological abnormalities in an in vivo model of cholesteryl ester storage disease [abstract no. 900]. J Hepatol. 2011;54(Suppl 1):S358.","journal-title":"J Hepatol"},{"issue":"S1","key":"479_CR14","first-page":"830A","volume":"56","author":"J Rutkowski","year":"2012","unstructured":"Rutkowski J, Burt AD, Leavitt M, et al. Recombinant human lysosomal acid lipase decreases hepatic macrophage aggregates and colocalized fibrosis in a rat model of lysosomal acid lipase deficiency [abstract no. 1351]. Hepatology. 2012;56(S1):830A.","journal-title":"Hepatology"},{"issue":"11","key":"479_CR15","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1501365","volume":"373","author":"BK Burton","year":"2015","unstructured":"Burton BK, Balwani M, Feillet F, et al. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med. 2015;373(11):1010\u201320.","journal-title":"N Engl J Med"},{"issue":"5","key":"479_CR16","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2014.06.022","volume":"61","author":"V Valayannopoulos","year":"2014","unstructured":"Valayannopoulos V, Malinova V, Honz\u00edk T, et al. Sebelipase alfa over 52\u00a0weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. J Hepatol. 2014;61(5):1135\u201342.","journal-title":"J Hepatol"},{"issue":"2","key":"479_CR17","first-page":"S59","volume":"114","author":"SA Jones","year":"2015","unstructured":"Jones SA, Plantaz D, Vara R, et al. Effect of sebelipase alfa on survival and liver function in infants with rapidly progressive lysosomal acid lipase deficiency [abstract no. 120]. Mol Genet Metab. 2015;114(2):S59.","journal-title":"Mol Genet Metab"},{"issue":"Suppl 2","key":"479_CR18","doi-asserted-by":"crossref","first-page":"S811","DOI":"10.1016\/S0168-8278(15)31408-2","volume":"62","author":"S Jones","year":"2015","unstructured":"Jones S, Plantaz D, Vara R, et al. Impact of sebelipase alfa on survival and liver function in infants with rapidly progressive lysosomal acid lipase deficiency [abstract no. P1212]. J Hepatol. 2015;62(Suppl 2):S811.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"479_CR19","first-page":"S160","volume":"37","author":"F Abel","year":"2014","unstructured":"Abel F, Whitley CB, Valayannopoulos V, et al. Effect of sebelipase alfa after 2\u00a0years in adults with lysosomal acid lipase deficiency [abstract no. P-445]. J Inherit Metab Dis. 2014;37(Suppl 1):S160.","journal-title":"J Inherit Metab Dis"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0479-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0479-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0479-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T10:13:50Z","timestamp":1567246430000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0479-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,9]]},"references-count":19,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["479"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0479-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,9]]}}}